Use of recombinant activated factor VII in massive obstetric haemorrhage.
Massive obstetric haemorrhage is a life-threatening emergency that remains a major cause of maternal mortality. Conventional management is aimed at optimising uterine tone, replacing circulating volume and blood products, and surgery to achieve haemostasis. Recently there have been numerous reports of the (unlicensed) use of recombinant activated factor VII in the management of major obstetric haemorrhage. We report our experience of using it in the treatment of major post-partum haemorrhage in four previously healthy parturients. The published reports of recombinant activated factor VII use in post-partum haemorrhage (unrelated to pre-existing coagulopathies) are compared.
Haynes
J
J
Obstetric Anaesthesia Department, Queen Charlotte's and Chelsea Hospital, and Department of Haematology, Hammersmith Hospital, London, UK.
Laffan
M
M
Plaat
F
F
D000328:Adult; D001778:Blood Coagulation Disorders / Q000209:etiology / Q000628:therapy; D002585:Cesarean Section / Q000379:methods; D003029:Coagulants / Q000627:therapeutic use*; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000150:complications; D006473:Postpartum Hemorrhage / Q000628:therapy*; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000150:complications
D003029:Coagulants; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa